test
test
test
test
test
test
test
test
test
test
Discussion about role of DPO in Anemia management
Discussion about role of DPO in Anemia management
Discussion about role of DPO in Anemia management
Discussion about role of DPO in Anemia management
Discussion about role of DPO in Anemia management
Discussion about role of DPO in Anemia management
Discussion about role of DPO in Anemia management
A recent study found that endothelin receptor antagonist atrasentan reduced pain-related events and use of analgesics such as non-steroidal anti-inflammatory drugs (NSAIDs) and opioids in selected patients with type 2 diabetes and chronic kidney disease (CKD). The study’s findings were published in the journal Kidney international.
SONAR trial was a randomized, double-blind, placebo-controlled study that included participants with type 2 diabetes and CKD. They were randomized to receive either atrasentan or placebo (n=1834 in each arm). The main outcome of the study was pain-related adverse events (AEs). Cox regression was used to analyze the effect of atrasentan on the risk of the first pain-related AE and the first prescription of analgesics in comparison with the placebo. Also, the Anderson-Gill method was used to assess effects on all pain-related AEs.
It was found that during the 2.2-year median follow-up, there were 1183 pain-related AEs. The first pain-related event rates in the atrasentan and placebo groups were 138.2 and 170.2 per 1000 person-years, respectively. Also, with atrasentan all pain-related AEs were reduced. Additionally, patients treated with atrasentan initiated fewer analgesics compared to the placebo.
From the above results, it can be concluded that atrasentan may be associated with reduced pain-related events and use of analgesics in carefully selected patients having type 2 diabetes and CKD.
A recent study found that endothelin receptor antagonist atrasentan reduced pain-related events and use of analgesics such as non-steroidal anti-inflammatory drugs (NSAIDs) and opioids in selected patients with type 2 diabetes and chronic kidney disease (CKD). The study’s findings were published in the journal Kidney international.
SONAR trial was a randomized, double-blind, placebo-controlled study that included participants with type 2 diabetes and CKD. They were randomized to receive either atrasentan or placebo (n=1834 in each arm). The main outcome of the study was pain-related adverse events (AEs). Cox regression was used to analyze the effect of atrasentan on the risk of the first pain-related AE and the first prescription of analgesics in comparison with the placebo. Also, the Anderson-Gill method was used to assess effects on all pain-related AEs.
It was found that during the 2.2-year median follow-up, there were 1183 pain-related AEs. The first pain-related event rates in the atrasentan and placebo groups were 138.2 and 170.2 per 1000 person-years, respectively. Also, with atrasentan all pain-related AEs were reduced. Additionally, patients treated with atrasentan initiated fewer analgesics compared to the placebo.
From the above results, it can be concluded that atrasentan may be associated with reduced pain-related events and use of analgesics in carefully selected patients having type 2 diabetes and CKD.
A recent study found that endothelin receptor antagonist atrasentan reduced pain-related events and use of analgesics such as non-steroidal anti-inflammatory drugs (NSAIDs) and opioids in selected patients with type 2 diabetes and chronic kidney disease (CKD). The study’s findings were published in the journal Kidney international.
SONAR trial was a randomized, double-blind, placebo-controlled study that included participants with type 2 diabetes and CKD. They were randomized to receive either atrasentan or placebo (n=1834 in each arm). The main outcome of the study was pain-related adverse events (AEs). Cox regression was used to analyze the effect of atrasentan on the risk of the first pain-related AE and the first prescription of analgesics in comparison with the placebo. Also, the Anderson-Gill method was used to assess effects on all pain-related AEs.
It was found that during the 2.2-year median follow-up, there were 1183 pain-related AEs. The first pain-related event rates in the atrasentan and placebo groups were 138.2 and 170.2 per 1000 person-years, respectively. Also, with atrasentan all pain-related AEs were reduced. Additionally, patients treated with atrasentan initiated fewer analgesics compared to the placebo.
From the above results, it can be concluded that atrasentan may be associated with reduced pain-related events and use of analgesics in carefully selected patients having type 2 diabetes and CKD.
According to a recent study, chronic kidney disease patients who received once-weekly (QW) recombinant human erythropoietin (rHuEPO), effectively converted to darbepoetin alfa administered subcutaneously every other week (Q2W), which was well tolerated. This study was published in the American Journal of Nephrology .
The STAAR (Simplify the Treatment of Anemia with Aranesp) was a multicenter, 52-week study that enrolled 524 subjects. The subgroup analysis of subjects who were on QW rHuEPO, were converted to 52-weeks of darbepoetin alfa therapy, administered subcutaneously. These subjects had either creatinine clearance < or = 70 ml/min or transferrin saturation > or = 20% and an estimated glomerular filtration rate < or = 60 ml/min. The primary endpoint of the study was mean Hb during evaluation.
It was found that the mean Hb +/- standard deviation was 11.2 +/- 1.27 g/dl at baseline while the least squares mean +/- SE was 11.4 +/- 0.04 during evaluation. Also, the mean +/- SD Q2W darbepoetin alfa dose was 49.7 +/- 21.9 microg and 48.9 +/- 35.5 microg at baseline and evaluation, respectively.
From the above results, it can be concluded that darbepoetin alfa was well tolerated in subjects who had chronic kidney disease, who were receiving QW rHuEPO and were effectively converted to Q2W darbepoetin alfa.
According to a recent study, chronic kidney disease patients who received once-weekly (QW) recombinant human erythropoietin (rHuEPO), effectively converted to darbepoetin alfa administered subcutaneously every other week (Q2W), which was well tolerated. This study was published in the American Journal of Nephrology .
The STAAR (Simplify the Treatment of Anemia with Aranesp) was a multicenter, 52-week study that enrolled 524 subjects. The subgroup analysis of subjects who were on QW rHuEPO, were converted to 52-weeks of darbepoetin alfa therapy, administered subcutaneously. These subjects had either creatinine clearance < or = 70 ml/min or transferrin saturation > or = 20% and an estimated glomerular filtration rate < or = 60 ml/min. The primary endpoint of the study was mean Hb during evaluation.
It was found that the mean Hb +/- standard deviation was 11.2 +/- 1.27 g/dl at baseline while the least squares mean +/- SE was 11.4 +/- 0.04 during evaluation. Also, the mean +/- SD Q2W darbepoetin alfa dose was 49.7 +/- 21.9 microg and 48.9 +/- 35.5 microg at baseline and evaluation, respectively.
From the above results, it can be concluded that darbepoetin alfa was well tolerated in subjects who had chronic kidney disease, who were receiving QW rHuEPO and were effectively converted to Q2W darbepoetin alfa.
According to a recent study, chronic kidney disease patients who received once-weekly (QW) recombinant human erythropoietin (rHuEPO), effectively converted to darbepoetin alfa administered subcutaneously every other week (Q2W), which was well tolerated. This study was published in the American Journal of Nephrology .
The STAAR (Simplify the Treatment of Anemia with Aranesp) was a multicenter, 52-week study that enrolled 524 subjects. The subgroup analysis of subjects who were on QW rHuEPO, were converted to 52-weeks of darbepoetin alfa therapy, administered subcutaneously. These subjects had either creatinine clearance < or = 70 ml/min or transferrin saturation > or = 20% and an estimated glomerular filtration rate < or = 60 ml/min. The primary endpoint of the study was mean Hb during evaluation.
It was found that the mean Hb +/- standard deviation was 11.2 +/- 1.27 g/dl at baseline while the least squares mean +/- SE was 11.4 +/- 0.04 during evaluation. Also, the mean +/- SD Q2W darbepoetin alfa dose was 49.7 +/- 21.9 microg and 48.9 +/- 35.5 microg at baseline and evaluation, respectively.
From the above results, it can be concluded that darbepoetin alfa was well tolerated in subjects who had chronic kidney disease, who were receiving QW rHuEPO and were effectively converted to Q2W darbepoetin alfa.
According to a recent study conducted in patients undergoing dialysis, a dose reduction conversion from epoetin to darbepoetin alfa using the starting dose conversion of 200:1, helped achieve a 30% dose savings. This study was published in the journal, NDT Plus.
This meta-analysis was done after sourcing articles from Medline and EmBase in order to find out all published trials investigating Erythropoiesis-stimulating agents (ESAs) for treatment in anaemic patients receiving dialysis. Prospective randomized controlled, non-randomized and observational studies that included patients on dialysis and which compared epoetin and darbepoetin alfa dosing were selected. Out of 573 articles, 9 studies fulfilled the eligibility criteria and were included in the analysis. Target haemoglobin levels were maintained before and after conversion in all the studies.
From the meta-analysis, it was found out that overall percentage dose savings attained was 30% when dialysis patients were converted from epoetin to darbepoetin alfa. Intravenous administration (33%) showed greater dose savings when compared to subcutaneous (27%) and between switch-over studies (31%) and RCTs (27%).
Based on the findings, it can be concluded that using an initial 200:1 conversion ratio, as indicated by the European Medicines Agency, after conversion from epoetin to darbepoetin alfa, an average 30% dose savings could be achieved through subsequent reduction in dose.
According to a recent study conducted in patients undergoing dialysis, a dose reduction conversion from epoetin to darbepoetin alfa using the starting dose conversion of 200:1, helped achieve a 30% dose savings. This study was published in the journal, NDT Plus.
This meta-analysis was done after sourcing articles from Medline and EmBase in order to find out all published trials investigating Erythropoiesis-stimulating agents (ESAs) for treatment in anaemic patients receiving dialysis. Prospective randomized controlled, non-randomized and observational studies that included patients on dialysis and which compared epoetin and darbepoetin alfa dosing were selected. Out of 573 articles, 9 studies fulfilled the eligibility criteria and were included in the analysis. Target haemoglobin levels were maintained before and after conversion in all the studies.
From the meta-analysis, it was found out that overall percentage dose savings attained was 30% when dialysis patients were converted from epoetin to darbepoetin alfa. Intravenous administration (33%) showed greater dose savings when compared to subcutaneous (27%) and between switch-over studies (31%) and RCTs (27%).
Based on the findings, it can be concluded that using an initial 200:1 conversion ratio, as indicated by the European Medicines Agency, after conversion from epoetin to darbepoetin alfa, an average 30% dose savings could be achieved through subsequent reduction in dose.
According to a recent study conducted in patients undergoing dialysis, a dose reduction conversion from epoetin to darbepoetin alfa using the starting dose conversion of 200:1, helped achieve a 30% dose savings. This study was published in the journal, NDT Plus.
This meta-analysis was done after sourcing articles from Medline and EmBase in order to find out all published trials investigating Erythropoiesis-stimulating agents (ESAs) for treatment in anaemic patients receiving dialysis. Prospective randomized controlled, non-randomized and observational studies that included patients on dialysis and which compared epoetin and darbepoetin alfa dosing were selected. Out of 573 articles, 9 studies fulfilled the eligibility criteria and were included in the analysis. Target haemoglobin levels were maintained before and after conversion in all the studies.
From the meta-analysis, it was found out that overall percentage dose savings attained was 30% when dialysis patients were converted from epoetin to darbepoetin alfa. Intravenous administration (33%) showed greater dose savings when compared to subcutaneous (27%) and between switch-over studies (31%) and RCTs (27%).
Based on the findings, it can be concluded that using an initial 200:1 conversion ratio, as indicated by the European Medicines Agency, after conversion from epoetin to darbepoetin alfa, an average 30% dose savings could be achieved through subsequent reduction in dose.
According to a recent study, mean haemoglobin levels and mean weekly darbepoetin alfa dose did not differ significantly in the subcutaneous and the intravenous groups. The study’s findings were published in the journal, Nephrology, dialysis, transplantation.
A multicenter, prospective, randomized trial included 114 patients, who were treated with subcutaneous darbepoetin alfa for at least 6 months. These participants were randomized in a 1:1 ratio to either continue with subcutaneous treatment of darbepoetin alfa (n=61) or were switched to the intravenous administration route (n=53). The darbepoetin dose and haemoglobin concentrations were assessed as per patient average taken at baseline i.e., Week -3 +/- 1, followed by Week 24 +/- 3 and Week 48 +/- 3.
It was observed that there were no significant changes in mean haemoglobin levels and mean weekly darbepoetin alfa dose in either of the treatment groups. From the above results, it may be concluded that darbepoetin alfa dose can be kept constant if patients are switched from subcutaneous to intravenous treatment.
According to a recent study, mean haemoglobin levels and mean weekly darbepoetin alfa dose did not differ significantly in the subcutaneous and the intravenous groups. The study’s findings were published in the journal, Nephrology, dialysis, transplantation.
A multicenter, prospective, randomized trial included 114 patients, who were treated with subcutaneous darbepoetin alfa for at least 6 months. These participants were randomized in a 1:1 ratio to either continue with subcutaneous treatment of darbepoetin alfa (n=61) or were switched to the intravenous administration route (n=53). The darbepoetin dose and haemoglobin concentrations were assessed as per patient average taken at baseline i.e., Week -3 +/- 1, followed by Week 24 +/- 3 and Week 48 +/- 3.
It was observed that there were no significant changes in mean haemoglobin levels and mean weekly darbepoetin alfa dose in either of the treatment groups. From the above results, it may be concluded that darbepoetin alfa dose can be kept constant if patients are switched from subcutaneous to intravenous treatment.
According to a recent study, mean haemoglobin levels and mean weekly darbepoetin alfa dose did not differ significantly in the subcutaneous and the intravenous groups. The study’s findings were published in the journal, Nephrology, dialysis, transplantation.
A multicenter, prospective, randomized trial included 114 patients, who were treated with subcutaneous darbepoetin alfa for at least 6 months. These participants were randomized in a 1:1 ratio to either continue with subcutaneous treatment of darbepoetin alfa (n=61) or were switched to the intravenous administration route (n=53). The darbepoetin dose and haemoglobin concentrations were assessed as per patient average taken at baseline i.e., Week -3 +/- 1, followed by Week 24 +/- 3 and Week 48 +/- 3.
It was observed that there were no significant changes in mean haemoglobin levels and mean weekly darbepoetin alfa dose in either of the treatment groups. From the above results, it may be concluded that darbepoetin alfa dose can be kept constant if patients are switched from subcutaneous to intravenous treatment.
